Trovagene Inc (NASDAQ:TROV)

0.8075
Delayed Data
As of Sep 19
 -0.0025 / -0.31%
Today’s Change
0.65
Today|||52-Week Range
12.96
-78.12%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$14.3M

Company Description

Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. Its focuses on developing PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky and Hovsep Melkonyan on August 4, 1999 and is headquartered in San Diego, CA.

Contact Information

TrovaGene, Inc.
11055 Flintkote Avenue
San Diego California 92121
P:(858) 952-7570
Investor Relations:

Employees

Shareholders

Other institutional7.17%
Mutual fund holders1.73%
Individual stakeholders0.65%

Top Executives

Thomas H. AdamsChairman & Chief Executive Officer
Mark ErlanderChief Scientific Officer
George SamuelVice President & General Counsel